Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impact PITTSBURGH, May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building ...

业绩总结 - Viatris Inc. 公司在北美地区的品牌产品包括Yupelri和Tyrvaya，以及现有的复杂通用药品如Wixela，预计全年总收入将实现2%的运营增长[5] - 欧洲业务预计将增长3%，主要受益于在意大利和法国等关键市场的广泛产品组合，以及新产品推出，如新兴市场的通用Aubagio[6] - 中国市场约95%的业务已经通过VBP，公司专注于继续执行并引入新产品，如Clopidogrel和Senarimad，以利用现有基础设施[13] 市场扩张和并购 - 公司寻求全球机会，利用全球基础设施，与生物制药公司合作，推动在美国以及全球范围内的增长[34] - 公司强调寻找具有全球权利的资产，以最大化价值，并强调资产的商业化比商业考虑更为重要[33] 负面信息 - Clopidogrel是一项用于预防急性心肌梗死的独特且新颖的临床试验[41] - 通过增加研究站点数量和重新与调查员亲密合作，Viatris正在加速Clopidogrel的招募速度[42][43] - Clopidogrel填补了心肌梗死治疗中的空白，通过自行注射药物来阻止心肌梗死的进展[45] - 临床试验的终点是在七天内死亡以及严重心肌梗死的发生率，旨在展示治疗组与安慰剂组之间的风险降低20%[50][51] - 患者是否正确注射药物对层次分析的影响，但最终结果将基于事件，而不考虑是否正确注射[53][54] - 监控数据表明患者在出现症状后30分钟内注射药物，并及时就医，且未出现严重出血迹象[55][57] - Viatris认为Clopidogrel是一种具有革命性意义的治疗方法，得到了临床界的支持[60][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other juris ...

Viatris Inc. (VTRS) delivered adjusted earnings of 67 cents per share in the first quarter of 2024, missing the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 77 cents in the year-ago quarter. Total revenues came in at $3.66 billion, down 1.7% year over year. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.7 million. Viatris’ stock is trading down in response to the first-quarter results mainly due to a miss on both ea ...

For the quarter ended March 2024, Viatris (VTRS) reported revenue of $3.66 billion, down 1.8% over the same period last year. EPS came in at $0.67, compared to $0.78 in the year-ago quarter. The reported revenue represents a surprise of -2.12% over the Zacks Consensus Estimate of $3.74 billion. With the consensus EPS estimate being $0.68, the EPS surprise was -1.47%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -1.47%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.67 per share when it actually produced earnings of $0.61, delivering a surprise of -8.96%. Over the last four quarters, the com ...

Q1 2024 Earnings May 9, 2024 ...

Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges • Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter • Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] • Reaffirms 2 ...

Viatris Inc. (VTRS)财报预期 - 分析师们最近对Viatris Inc. (VTRS)盈利预期进行了积极修订[1][2] - VTRS本季度的最准确预估为每股69美分，高于Zacks Consensus Estimate的68美分，显示分析师们最近上调了对VTRS的预估[3] - 公司的Zacks Earnings ESP为+0.74%，显示出积极的盈利预期[3] - 公司的Zacks Rank为3，加上盈利预期积极，投资者可能考虑在财报发布前考虑购买该股票[5] - 最近的盈利预估修订表明Viatris前景看好，可能会在即将发布的财报中取得好成绩[6]

Viatris (VTRS) , a global healthcare company, is scheduled to report first-quarter results on May 9, 2024. The company’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.78%. In the last reported quarter, the company missed on earnings by 8.96%. Factors to Consider Viatris reports revenues under two divisions in terms of product category —brands and generics. Brand business makes up about two-thirds of the company’s portfolio. This categor ...